by Eli Lilly
Eligible for BMI of 30 kg/m2 or more
Mounjaro (tirzepatide) is an innovative injectable prescription medication for chronic weight management in adults. It combines the effects of GIP and GLP-1 hormones to regulate appetite and improve metabolic function.
As the first dual GIP and GLP-1 receptor agonist, Mounjaro offers superior weight loss results compared to single-action medications. It targets multiple pathways involved in weight regulation for comprehensive effects.
Clinical trials show Mounjaro can help patients lose up to 22% of their body weight when combined with lifestyle changes. The medication follows a structured dose escalation to optimize tolerability.
Mounjaro is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like type 2 diabetes.
Mounjaro treatment begins with a 5-week dose escalation period (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg) before reaching the maintenance dose of 15mg weekly. This gradual increase helps minimize side effects.
Mounjaro is a prescription-only medication. You'll need to complete a consultation with one of our healthcare professionals to determine if it's suitable for you.